Zydus gets USFDA approval for Lansoprazole
Drug comes under anti-ulcerant segment
 "Zydus gets USFDA approval for Lansoprazole")
Zydus Cadila has said that it has received final approval to market Lansoprazole DR capsules in the strengths of 15 mg and 30 mg from US FDA.
The drug falls in anti - ulcerant segment, it said in a filing to exchanges. The estimated sales of Lansoprazole was $ 501 million in 2012, the company said.
The drug falls in anti - ulcerant segment, it said in a filing to exchanges. The estimated sales of Lansoprazole was $ 501 million in 2012, the company said.